首页 > 最新文献

Pharmaceutical Research最新文献

英文 中文
The Role of Artificial Intelligence and Machine Learning in Accelerating the Discovery and Development of Nanomedicine. 人工智能和机器学习在加速纳米医学发现和发展中的作用。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI: 10.1007/s11095-024-03798-9
Vivek Agrahari, Yahya E Choonara, Mitra Mosharraf, Sravan Kumar Patel, Fan Zhang

The unique potential of nanomedicine to address challenging health issues is rapidly advancing the field, leading to the generation of more effective products. However, these complex systems often pose several challenges with respect to their design for specific functionality, scalable manufacturing, characterization, quality control, and clinical translation. In this regard, the application of artificial intelligence (AI) and machine learning (ML) approaches can enable faster and more accurate data assessment, identifying trends and predicting outcomes, leading to efficient nanomedicine product development. This perspective paper discusses the potential of AI and ML in nanomedicine product development with a focus on their applications in discovery, assessment, manufacturing, and clinical trials. The potential limitations of AI and ML approaches in nanomedicine product development are also covered.

纳米医学在解决具有挑战性的健康问题方面的独特潜力正在迅速推动该领域的发展,从而产生更有效的产品。然而,这些复杂的系统通常会在特定功能的设计、可扩展的制造、表征、质量控制和临床翻译方面提出一些挑战。在这方面,人工智能(AI)和机器学习(ML)方法的应用可以实现更快,更准确的数据评估,识别趋势和预测结果,从而实现高效的纳米药物产品开发。本文讨论了人工智能和机器学习在纳米药物产品开发中的潜力,重点介绍了它们在发现、评估、制造和临床试验中的应用。人工智能和机器学习方法在纳米药物产品开发中的潜在局限性也被涵盖。
{"title":"The Role of Artificial Intelligence and Machine Learning in Accelerating the Discovery and Development of Nanomedicine.","authors":"Vivek Agrahari, Yahya E Choonara, Mitra Mosharraf, Sravan Kumar Patel, Fan Zhang","doi":"10.1007/s11095-024-03798-9","DOIUrl":"10.1007/s11095-024-03798-9","url":null,"abstract":"<p><p>The unique potential of nanomedicine to address challenging health issues is rapidly advancing the field, leading to the generation of more effective products. However, these complex systems often pose several challenges with respect to their design for specific functionality, scalable manufacturing, characterization, quality control, and clinical translation. In this regard, the application of artificial intelligence (AI) and machine learning (ML) approaches can enable faster and more accurate data assessment, identifying trends and predicting outcomes, leading to efficient nanomedicine product development. This perspective paper discusses the potential of AI and ML in nanomedicine product development with a focus on their applications in discovery, assessment, manufacturing, and clinical trials. The potential limitations of AI and ML approaches in nanomedicine product development are also covered.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2289-2297"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142771237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and In-Vitro Evaluation of Doxorubicin-Loaded Methacrylate Gelatin (GelMa)-Acrylamide Hydrogels for the Treatment of Malignant Pleural Mesothelioma. 多柔比星负载甲基丙烯酸明胶-丙烯酰胺水凝胶治疗恶性胸膜间皮瘤的研制及体外评价。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-04 DOI: 10.1007/s11095-024-03794-z
Nishant S Kulkarni, Gautam Chauhan, Mural Quadros, Dnyandev G Gadhave, Vivek Gupta

Objective: Malignant pleural mesothelioma (MPM) is the most prevalent subtype of malignant mesothelioma that affects the pleural lining of the lungs. Conventionally, chemotherapy via systemic injections has shown limited efficacy due to off-target effects, and inefficacious deposition at the disease site. In our previous study, we reported the development and optimization of UV-initiated methacrylate gelatin (GelMa)-acrylamide based hydrogel formulation for local intracavitary administration of therapies. The current study utilizes a pre-established GelMa formulation for delivering a small molecule chemotherapeutic agent, Doxorubicin (Dox), against in-vitro MPM models.

Methods: Dox-loaded hydrogel (DLH) precursor solution was prepared by dissolving Dox in the precursor solution. The gels were characterized for physical properties such as gelling time, swelling index, bio adhesion, and injectability and were compared to blank hydrogels. Dox-loaded hydrogels were also tested for therapeutic efficacy in MPM cells in various 2D and 3D cell culture models.

Results: It was revealed that Dox-loaded hydrogels retained similar physical properties, including gelling time (< 25 s), swelling index (~ 1,200%), bio-adhesion (> 20 g detachment force), and injectability (< 2N force for injecting precursor), compared to blank hydrogels. Moreover, the gel formulation effectively sustained the release of hydrophilic Dox HCl over a period of 12 days by increasing the degree of crosslinking between GelMa and its crosslinkers. Further, the therapeutic efficacy of Dox was retained even after loading into hydrogels, indicating that no chemical interactions took place between gel excipients and the drug. Studies in MPM cell-based models revealed that DLH showed excellent potential in inhibiting 2D and 3D cell growth, with DLH being more effective than plain Dox in suppressing tumor growth in 3D spheroid models.

Conclusions: Overall, the results of the present study suggest that Dox-loaded hydrogels (DLH) may be a good candidate for efficacy study in preclinical mesothelioma models, with strong potential for clinical translation.

目的:恶性胸膜间皮瘤(Malignant pleural mesothelioma, MPM)是影响肺胸膜层的最常见的恶性间皮瘤亚型。传统上,全身注射化疗由于脱靶效应和疾病部位的无效沉积而显示出有限的疗效。在我们之前的研究中,我们报道了紫外线引发的甲基丙烯酸明胶(GelMa)-丙烯酰胺基水凝胶配方的开发和优化,用于局部腔内给药。目前的研究利用预先建立的GelMa配方,为体外MPM模型提供小分子化疗药物阿霉素(Dox)。方法:将Dox溶解于前驱体溶液中制备负载Dox水凝胶(DLH)前驱体溶液。表征了凝胶的物理性质,如凝胶时间、肿胀指数、生物粘附性和可注射性,并与空白水凝胶进行了比较。在各种2D和3D细胞培养模型中,还测试了负载dox的水凝胶对MPM细胞的治疗效果。结果:结果表明,载dox水凝胶具有相似的物理性质,包括成胶时间(20 g分离力)和可注射性。结论:总体而言,本研究结果表明,载dox水凝胶(DLH)可能是临床前间皮瘤模型疗效研究的良好候选者,具有很强的临床转化潜力。
{"title":"Development and In-Vitro Evaluation of Doxorubicin-Loaded Methacrylate Gelatin (GelMa)-Acrylamide Hydrogels for the Treatment of Malignant Pleural Mesothelioma.","authors":"Nishant S Kulkarni, Gautam Chauhan, Mural Quadros, Dnyandev G Gadhave, Vivek Gupta","doi":"10.1007/s11095-024-03794-z","DOIUrl":"10.1007/s11095-024-03794-z","url":null,"abstract":"<p><strong>Objective: </strong>Malignant pleural mesothelioma (MPM) is the most prevalent subtype of malignant mesothelioma that affects the pleural lining of the lungs. Conventionally, chemotherapy via systemic injections has shown limited efficacy due to off-target effects, and inefficacious deposition at the disease site. In our previous study, we reported the development and optimization of UV-initiated methacrylate gelatin (GelMa)-acrylamide based hydrogel formulation for local intracavitary administration of therapies. The current study utilizes a pre-established GelMa formulation for delivering a small molecule chemotherapeutic agent, Doxorubicin (Dox), against in-vitro MPM models.</p><p><strong>Methods: </strong>Dox-loaded hydrogel (DLH) precursor solution was prepared by dissolving Dox in the precursor solution. The gels were characterized for physical properties such as gelling time, swelling index, bio adhesion, and injectability and were compared to blank hydrogels. Dox-loaded hydrogels were also tested for therapeutic efficacy in MPM cells in various 2D and 3D cell culture models.</p><p><strong>Results: </strong>It was revealed that Dox-loaded hydrogels retained similar physical properties, including gelling time (< 25 s), swelling index (~ 1,200%), bio-adhesion (> 20 g detachment force), and injectability (< 2N force for injecting precursor), compared to blank hydrogels. Moreover, the gel formulation effectively sustained the release of hydrophilic Dox HCl over a period of 12 days by increasing the degree of crosslinking between GelMa and its crosslinkers. Further, the therapeutic efficacy of Dox was retained even after loading into hydrogels, indicating that no chemical interactions took place between gel excipients and the drug. Studies in MPM cell-based models revealed that DLH showed excellent potential in inhibiting 2D and 3D cell growth, with DLH being more effective than plain Dox in suppressing tumor growth in 3D spheroid models.</p><p><strong>Conclusions: </strong>Overall, the results of the present study suggest that Dox-loaded hydrogels (DLH) may be a good candidate for efficacy study in preclinical mesothelioma models, with strong potential for clinical translation.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2331-2345"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Underlying Cause and Solution to the Poor Size Exclusion Chromatography Performance of Antibody-Drug Conjugates. 抗体-药物共轭物尺寸排阻色谱性能不佳的根本原因和解决方案。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-13 DOI: 10.1007/s11095-024-03796-x
Jian-Zhong Liu, Chao-Yang Du, Han Gao, Haibin Wang, Feng Hu, Wei-Jie Fang

Purposes: Antibody-drug conjugate (ADC) size variants are frequently assessed by size exclusion chromatography (SEC). However, poor chromatography performance is often observed during SEC analysis. Existing studies have primarily focused on qualitatively describing non-specific interactions between ADCs and the column matrix. The purposes of the current study are to introduce an underlying cause from a novel perspective on the protein-protein interaction (PPI) mechanism, characterized by quantifying diffusion interaction parameter (kD) values, and to provide several strategies to reduce PPI and improve column performance during SEC analysis.

Methods: Two kinds of ADCs with varying hydrophobicity properties and their corresponding monoclonal antibodies are used as models. The hydrophobicity of these products was verified using the relative calculated logarithm of the partition coefficient of a substance in n-octanol (oil) and water (rCLogP) and reversed-phase high performance liquid chromatography (RP-HPLC), and the size variants were analyzed using SEC. Finally, the PPI was characterized by kD values of these four products.

Results: The results of rCLogP and RP-HPLC indicated that ADC-1 is relatively hydrophobic, whereas ADC-2 is relatively hydrophilic. In the SEC analysis of the ADC-1, substituting sodium chloride with L-arginine hydrochloride or adding a specific concentration of acetonitrile as an organic solvent to the mobile phase resulted in reduced PPI and enhanced column performance. Conversely, the impact on ADC-2 was negligible.

Conclusions: This study provides insights into improving the performance of SEC analysis for ADCs through strategies involving alterations in mobile phase composition. The changes in column performance can be quantitatively explained by the PPI mechanism.

目的:抗体药物共轭物(ADC)的尺寸变异经常通过尺寸排阻色谱法(SEC)进行评估。然而,在 SEC 分析过程中经常会发现色谱性能不佳。现有研究主要侧重于定性描述 ADC 与色谱柱基质之间的非特异性相互作用。本研究的目的是从蛋白质-蛋白质相互作用(PPI)机制的新角度介绍其根本原因,通过量化扩散相互作用参数(kD)值来描述其特征,并提供几种策略来减少 PPI 并改善 SEC 分析过程中的色谱柱性能:方法:以两种疏水性不同的 ADC 及其相应的单克隆抗体为模型。用物质在正辛醇(油)和水中分配系数的相对计算对数(rCLogP)和反相高效液相色谱法(RP-HPLC)验证了这些产品的疏水性,并用 SEC 分析了它们的粒度变化。最后,根据这四种产物的 kD 值对 PPI 进行了表征:rCLogP和RP-HPLC的结果表明,ADC-1相对疏水,而ADC-2相对亲水。在对 ADC-1 进行 SEC 分析时,用 L- 精氨酸盐酸盐代替氯化钠或在流动相中添加特定浓度的乙腈作为有机溶剂可降低 PPI 并提高色谱柱性能。相反,对 ADC-2 的影响可以忽略不计:这项研究为通过改变流动相组成的策略来提高 ADC 的 SEC 分析性能提供了启示。色谱柱性能的变化可以用 PPI 机制来定量解释。
{"title":"An Underlying Cause and Solution to the Poor Size Exclusion Chromatography Performance of Antibody-Drug Conjugates.","authors":"Jian-Zhong Liu, Chao-Yang Du, Han Gao, Haibin Wang, Feng Hu, Wei-Jie Fang","doi":"10.1007/s11095-024-03796-x","DOIUrl":"10.1007/s11095-024-03796-x","url":null,"abstract":"<p><strong>Purposes: </strong>Antibody-drug conjugate (ADC) size variants are frequently assessed by size exclusion chromatography (SEC). However, poor chromatography performance is often observed during SEC analysis. Existing studies have primarily focused on qualitatively describing non-specific interactions between ADCs and the column matrix. The purposes of the current study are to introduce an underlying cause from a novel perspective on the protein-protein interaction (PPI) mechanism, characterized by quantifying diffusion interaction parameter (k<sub>D</sub>) values, and to provide several strategies to reduce PPI and improve column performance during SEC analysis.</p><p><strong>Methods: </strong>Two kinds of ADCs with varying hydrophobicity properties and their corresponding monoclonal antibodies are used as models. The hydrophobicity of these products was verified using the relative calculated logarithm of the partition coefficient of a substance in n-octanol (oil) and water (rCLogP) and reversed-phase high performance liquid chromatography (RP-HPLC), and the size variants were analyzed using SEC. Finally, the PPI was characterized by k<sub>D</sub> values of these four products.</p><p><strong>Results: </strong>The results of rCLogP and RP-HPLC indicated that ADC-1 is relatively hydrophobic, whereas ADC-2 is relatively hydrophilic. In the SEC analysis of the ADC-1, substituting sodium chloride with L-arginine hydrochloride or adding a specific concentration of acetonitrile as an organic solvent to the mobile phase resulted in reduced PPI and enhanced column performance. Conversely, the impact on ADC-2 was negligible.</p><p><strong>Conclusions: </strong>This study provides insights into improving the performance of SEC analysis for ADCs through strategies involving alterations in mobile phase composition. The changes in column performance can be quantitatively explained by the PPI mechanism.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2299-2317"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which Models are USEful? 哪些模型是有用的?
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI: 10.1007/s11095-024-03799-8
John P Prybylski
{"title":"Which Models are USEful?","authors":"John P Prybylski","doi":"10.1007/s11095-024-03799-8","DOIUrl":"10.1007/s11095-024-03799-8","url":null,"abstract":"","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2271-2274"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142771239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of "In Use" Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence. “在用”给药对阿昔洛韦乳膏局部产品变形和皮肤渗透的影响:生物等效性的意义。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-09 DOI: 10.1007/s11095-024-03797-w
Sarika N Namjoshi, K C Telaprolu, Jeffrey E Grice, Heather A E Benson, S G Raney, Michael S Roberts, Yousuf H Mohammed

Purpose: Typical clinical "in use" conditions for topical semisolids involve their application as a thin film, often with rubbing that can induce metamorphic stress. Yet, product quality and performance tests often characterize the manufactured product, and may not consider product metamorphosis (e.g., shear history) during dispensing and administration. This work sought to elucidate how such metamorphosis might alter product quality and performance.

Methods: We evaluated the effect of "in use" stresses on drug crystal metamorphosis in acyclovir creams by optical microscopy. The amount of dissolved acyclovir was determined by separation of the cream base by ultra-centrifugation and quantification by HPLC. IVPT was undertaken on Zovirax® US and Aciclostad® comparing static and "in use" application of a finite dose. A mechanistic IVPT study was also conducted to understand the influence of acyclovir particle size reduction by "in use" rubbing on skin permeation.

Results: Reduction in acyclovir particle size was seen after "in use" rubbing with increases in the amount of dissolved acyclovir after rubbing (30 and 60 s) compared to static for both products. "In use" application resulted in significantly higher acyclovir permeation from both products. The mechanistic IVPT study proved the role of product metamorphosis.

Conclusion: These results highlight the role of metamorphosis of product microstructure and its influence on performance.

目的:局部半固体的典型临床“在用”条件包括其作为薄膜的应用,经常与摩擦,可引起变形应力。然而,产品质量和性能测试通常是制成品的特征,可能不会考虑在配药和给药过程中的产品变形(例如剪切历史)。这项工作试图阐明如何这样的蜕变可能改变产品的质量和性能。方法:用光学显微镜观察“在用”应力对阿昔洛韦乳膏中药物晶体变形的影响。采用超离心分离膏碱,高效液相色谱法定量测定阿昔洛韦的溶出量。对Zovirax®US和Aciclostad®进行了IVPT,比较了有限剂量的静态应用和“在用”应用。一项机械的IVPT研究也被进行,以了解“在用”摩擦对皮肤渗透的阿昔洛韦粒径减少的影响。结果:两种产品在“使用中”摩擦后,阿昔洛韦颗粒大小减小,摩擦后(30和60秒)阿昔洛韦的溶解量增加。“在用”应用导致两种产品明显更高的阿昔洛韦渗透。机械性IVPT研究证实了产物变态的作用。结论:这些结果突出了产品微观结构变形的作用及其对性能的影响。
{"title":"Effect of \"In Use\" Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence.","authors":"Sarika N Namjoshi, K C Telaprolu, Jeffrey E Grice, Heather A E Benson, S G Raney, Michael S Roberts, Yousuf H Mohammed","doi":"10.1007/s11095-024-03797-w","DOIUrl":"10.1007/s11095-024-03797-w","url":null,"abstract":"<p><strong>Purpose: </strong>Typical clinical \"in use\" conditions for topical semisolids involve their application as a thin film, often with rubbing that can induce metamorphic stress. Yet, product quality and performance tests often characterize the manufactured product, and may not consider product metamorphosis (e.g., shear history) during dispensing and administration. This work sought to elucidate how such metamorphosis might alter product quality and performance.</p><p><strong>Methods: </strong>We evaluated the effect of \"in use\" stresses on drug crystal metamorphosis in acyclovir creams by optical microscopy. The amount of dissolved acyclovir was determined by separation of the cream base by ultra-centrifugation and quantification by HPLC. IVPT was undertaken on Zovirax<sup>®</sup> US and Aciclostad<sup>®</sup> comparing static and \"in use\" application of a finite dose. A mechanistic IVPT study was also conducted to understand the influence of acyclovir particle size reduction by \"in use\" rubbing on skin permeation.</p><p><strong>Results: </strong>Reduction in acyclovir particle size was seen after \"in use\" rubbing with increases in the amount of dissolved acyclovir after rubbing (30 and 60 s) compared to static for both products. \"In use\" application resulted in significantly higher acyclovir permeation from both products. The mechanistic IVPT study proved the role of product metamorphosis.</p><p><strong>Conclusion: </strong>These results highlight the role of metamorphosis of product microstructure and its influence on performance.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2391-2401"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glass Silicone Oil Free Pre-filled Syringe as Primary Container in Autoinjector. 无硅油预充式玻璃注射器作为自动注射器的主容器。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-05 DOI: 10.1007/s11095-024-03795-y
Xi Zhao, Yueli Chen, Hassen Hamzaoui, Xiaona Wen, Jing Song, Kaitlin Wang, Guangli Hu

Objective: Pre-filled syringes (PFSs) have become popular as a convenient and cost-effective container closure system for delivering biotherapeutics. However, standard siliconized PFSs may compromise the stability of therapeutic proteins due to their exposure to the silicone oil-water interface. To address this concern, silicone oil-free (SOF) glass syringes coupled with silicone-oil free plunger stoppers have been developed. This study aims to compare the impact of silicone oil-free (SOF) and siliconized syringes as primary container on protein stability and device functionality of the combination products.

Methods: The stability of proteins with different modalities was assessed in SOF and siliconized 1 mL glass syringes for up to 6 months at 5℃, 25℃, and 40℃ with levels of subvisible particles and soluble aggregate determined by micro-flow imaging (MFI) and ultra performance size-exclusion chromatography (UP-SEC). The functionality of SOF glass syringes, including break loose force, extrusion force and delivery time in autoinjectors, was evaluated at different time points during the stability study. Additionally, SOF glass syringes were filled with viscosity surrogate ranging from 1 to 90 cP to understand the impact of solution viscosity on break loose force, extrusion force, and autoinjector delivery time.

Results: SOF demonstrates compatibility with proteins and exhibited significantly low particle counts compared to siliconized PFS. SOF syringes show significantly higher break-loose and extrusion forces. However, unlike siliconized syringes where silicone oil migration increases extrusion force, no significant change in functionality was observed in SOF glass syringe during stability testing. Overall, SOF glass syringes showed great potential as an alternative package for biologics with comparable performance on functionality as siliconized PFS.

Conclusions: The combination of SOF glass and its PTFE coated stopper presents a new primary container closure system with both adequate protein stability and desired functionality features.

目的:预充式注射器(pfs)作为一种方便、经济的容器封闭系统已成为生物治疗药物输送的热门工具。然而,由于暴露于硅油-水界面,标准硅化PFSs可能会损害治疗蛋白的稳定性。为了解决这个问题,无硅油(SOF)玻璃注射器与无硅油柱塞已经开发出来。本研究旨在比较无硅油(SOF)和硅化注射器作为主要容器对组合产品蛋白质稳定性和设备功能的影响。方法:在5℃、25℃和40℃条件下,采用微流成像(MFI)和超高效粒径隔离层析(up - sec)法测定不同形态蛋白在sofl和硅化1ml玻璃注射器中长达6个月的稳定性。在稳定性研究过程中,对soff玻璃注射器在不同时间点的功能进行了评估,包括自动进样器的断裂力、挤出力和给药时间。此外,在SOF玻璃注射器中填充1 ~ 90 cP的粘度替代物,以了解溶液粘度对断裂力、挤出力和自动进样器给药时间的影响。结果:与硅化PFS相比,sofs具有与蛋白质的相容性,并且具有显著的低颗粒计数。软注射器显示出明显更高的断裂和挤压力。然而,与硅油迁移增加挤出力的硅化注射器不同,SOF玻璃注射器在稳定性测试中没有观察到明显的功能变化。总的来说,SOF玻璃注射器作为生物制剂的替代包装显示出巨大的潜力,其功能性能与硅化PFS相当。结论:SOF玻璃及其PTFE涂层塞的组合提供了一种新的初级容器封闭系统,具有足够的蛋白质稳定性和理想的功能特征。
{"title":"Glass Silicone Oil Free Pre-filled Syringe as Primary Container in Autoinjector.","authors":"Xi Zhao, Yueli Chen, Hassen Hamzaoui, Xiaona Wen, Jing Song, Kaitlin Wang, Guangli Hu","doi":"10.1007/s11095-024-03795-y","DOIUrl":"10.1007/s11095-024-03795-y","url":null,"abstract":"<p><strong>Objective: </strong>Pre-filled syringes (PFSs) have become popular as a convenient and cost-effective container closure system for delivering biotherapeutics. However, standard siliconized PFSs may compromise the stability of therapeutic proteins due to their exposure to the silicone oil-water interface. To address this concern, silicone oil-free (SOF) glass syringes coupled with silicone-oil free plunger stoppers have been developed. This study aims to compare the impact of silicone oil-free (SOF) and siliconized syringes as primary container on protein stability and device functionality of the combination products.</p><p><strong>Methods: </strong>The stability of proteins with different modalities was assessed in SOF and siliconized 1 mL glass syringes for up to 6 months at 5℃, 25℃, and 40℃ with levels of subvisible particles and soluble aggregate determined by micro-flow imaging (MFI) and ultra performance size-exclusion chromatography (UP-SEC). The functionality of SOF glass syringes, including break loose force, extrusion force and delivery time in autoinjectors, was evaluated at different time points during the stability study. Additionally, SOF glass syringes were filled with viscosity surrogate ranging from 1 to 90 cP to understand the impact of solution viscosity on break loose force, extrusion force, and autoinjector delivery time.</p><p><strong>Results: </strong>SOF demonstrates compatibility with proteins and exhibited significantly low particle counts compared to siliconized PFS. SOF syringes show significantly higher break-loose and extrusion forces. However, unlike siliconized syringes where silicone oil migration increases extrusion force, no significant change in functionality was observed in SOF glass syringe during stability testing. Overall, SOF glass syringes showed great potential as an alternative package for biologics with comparable performance on functionality as siliconized PFS.</p><p><strong>Conclusions: </strong>The combination of SOF glass and its PTFE coated stopper presents a new primary container closure system with both adequate protein stability and desired functionality features.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2319-2329"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Photodegradation of Dacarbazine Catalyzed by Vitamin B2 and Flavin Adenine Dinucleotide Under Visible-Light Irradiation. 维生素B2和黄素腺嘌呤二核苷酸在可见光下催化达卡巴嗪的光降解。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-18 DOI: 10.1007/s11095-024-03802-2
Yuka Kimura, Mayuko Suga, Kayo Nakamura, Hidetsugu Tabata, Tetsuta Oshitari, Hideaki Natsugari, Hideyo Takahashi

Purpose: Drug photodegradation is a matter of great concern because it can result in potency loss and adverse side effects. This study examines the light-induced degradation of dacarbazine catalyzed by vitamin B2 and flavin adenine dinucleotide (FAD) under light-emitting diode (LED) or fluorescent light irradiation.

Methods: Dacarbazine was irradiated with LED (405 nm) or fluorescent light in the presence of various equivalents of vitamin B2 or FAD. The photodegradation of the drug in D2O was monitored by 1H nuclear magnetic resonance spectroscopy.

Results: Dacarbazine dissolved in D2O decomposed in the presence of vitamin B2 or FAD under irradiation with LED or fluorescent light. The decomposition products were 2-azahypoxanthine 2, which has previously been observed after light irradiation in the absence of vitamin B2, and 1H-imidazole-5-carboxamide 6, a new product formed in the presence of vitamin B2. Irradiation with LED light was more effective than irradiation with fluorescent light in degrading dacarbazine.

Conclusion: Vitamin B2 and FAD induced dacarbazine photodegradation. Thus, the interfusion of vitamin B2 or FAD under excessive light exposure should be avoided during the intravenous administration of dacarbazine.

目的:药物光降解是一个值得关注的问题,因为它可能导致效力损失和不良副作用。本文研究了维生素B2和黄素腺嘌呤二核苷酸(FAD)在发光二极管(LED)和荧光灯照射下对达卡巴嗪的光诱导降解。方法:用LED (405 nm)或荧光灯在不同当量的维生素B2或FAD存在下照射达卡巴嗪。1H核磁共振波谱法监测药物在D2O中的光降解。结果:在LED或荧光灯照射下,溶解于D2O中的达卡巴嗪在维生素B2或FAD存在下分解。分解产物是2-氮杂次黄嘌呤2,这是之前在没有维生素B2的情况下光照射后观察到的产物,以及在维生素B2存在下形成的新产物1h -咪唑-5-羧酰胺6。LED光照射对达卡巴嗪的降解效果优于荧光照射。结论:维生素B2和FAD可诱导达卡巴嗪的光降解。因此,在静脉注射达卡巴嗪时,应避免维生素B2或FAD在过度光照下的灌注。
{"title":"Photodegradation of Dacarbazine Catalyzed by Vitamin B<sub>2</sub> and Flavin Adenine Dinucleotide Under Visible-Light Irradiation.","authors":"Yuka Kimura, Mayuko Suga, Kayo Nakamura, Hidetsugu Tabata, Tetsuta Oshitari, Hideaki Natsugari, Hideyo Takahashi","doi":"10.1007/s11095-024-03802-2","DOIUrl":"10.1007/s11095-024-03802-2","url":null,"abstract":"<p><strong>Purpose: </strong>Drug photodegradation is a matter of great concern because it can result in potency loss and adverse side effects. This study examines the light-induced degradation of dacarbazine catalyzed by vitamin B<sub>2</sub> and flavin adenine dinucleotide (FAD) under light-emitting diode (LED) or fluorescent light irradiation.</p><p><strong>Methods: </strong>Dacarbazine was irradiated with LED (405 nm) or fluorescent light in the presence of various equivalents of vitamin B<sub>2</sub> or FAD. The photodegradation of the drug in D<sub>2</sub>O was monitored by <sup>1</sup>H nuclear magnetic resonance spectroscopy.</p><p><strong>Results: </strong>Dacarbazine dissolved in D<sub>2</sub>O decomposed in the presence of vitamin B<sub>2</sub> or FAD under irradiation with LED or fluorescent light. The decomposition products were 2-azahypoxanthine 2, which has previously been observed after light irradiation in the absence of vitamin B<sub>2</sub>, and 1H-imidazole-5-carboxamide 6, a new product formed in the presence of vitamin B<sub>2</sub>. Irradiation with LED light was more effective than irradiation with fluorescent light in degrading dacarbazine.</p><p><strong>Conclusion: </strong>Vitamin B<sub>2</sub> and FAD induced dacarbazine photodegradation. Thus, the interfusion of vitamin B<sub>2</sub> or FAD under excessive light exposure should be avoided during the intravenous administration of dacarbazine.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2363-2375"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy. 肿瘤免疫治疗中抗pd - l1多肽开发的多价性探索。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-12-01 Epub Date: 2024-12-17 DOI: 10.1007/s11095-024-03803-1
Umar-Farouk Mamani, Mohammed Nurudeen Ibrahim, Yanli Liu, John Fetse, Chien-Yu Lin, Sashi Kandel, Maryam Nakhjiri, Sushil Koirala, Yuhan Guo, Mohammed Alahmari, Kun Cheng

Purpose: The PD-1/PD-L1 pathway is one of the most effective immune checkpoint pathways utilized for cancer immunotherapy. Despite the success of anti-PD-1/PD-L1 mAbs, there is growing interest in developing low molecular weight anti-PD-1/PD-1 agents, such as peptides, because of their improved tumor penetration. We recently developed a small anti-PD-L1 peptide and demonstrated its promising anti-tumor activity. In this study, we investigate multivalency as a strategy to increase the binding avidity and blocking efficiency of the anti-PD-L1 peptide.

Methods: Multivalent peptide inhibitors are designed with multiple copies of a peptide inhibitor in a single molecule. We synthesized peptides with different valences and examined their activity. We also investigated how spacer length affects the activity of these multivalent peptides.

Results: Using this strategy, we developed a multivalent peptide that demonstrated approximately 40 times higher blocking efficiency and improved stability compared to the original peptide. Increasing the valency enhanced the peptide's specificity, which is essential for minimizing side effects.

Conclusions: Multivalency approach represents a promising platform for improving the efficacy of peptide-based checkpoint inhibitors.

目的:PD-1/PD-L1 通路是癌症免疫疗法中最有效的免疫检查点通路之一。尽管抗PD-1/PD-L1 mAbs取得了成功,但人们对开发低分子量抗PD-1/PD-1制剂(如多肽)的兴趣与日俱增,因为它们的肿瘤穿透力更强。我们最近开发了一种小型抗 PD-L1 肽,并证明了其具有良好的抗肿瘤活性。在本研究中,我们将多价作为一种策略来提高抗 PD-L1 肽的结合活性和阻断效率:多价肽抑制剂是在单个分子中设计多个拷贝的肽抑制剂。我们合成了不同价位的多肽,并检测了它们的活性。我们还研究了间隔长度如何影响这些多价肽的活性:结果:利用这种策略,我们开发出了一种多价肽,与原始肽相比,它的阻断效率提高了约 40 倍,稳定性也得到了改善。提高多价肽的特异性对减少副作用至关重要:多价方法是提高基于多肽的检查点抑制剂疗效的一个前景广阔的平台。
{"title":"Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy.","authors":"Umar-Farouk Mamani, Mohammed Nurudeen Ibrahim, Yanli Liu, John Fetse, Chien-Yu Lin, Sashi Kandel, Maryam Nakhjiri, Sushil Koirala, Yuhan Guo, Mohammed Alahmari, Kun Cheng","doi":"10.1007/s11095-024-03803-1","DOIUrl":"10.1007/s11095-024-03803-1","url":null,"abstract":"<p><strong>Purpose: </strong>The PD-1/PD-L1 pathway is one of the most effective immune checkpoint pathways utilized for cancer immunotherapy. Despite the success of anti-PD-1/PD-L1 mAbs, there is growing interest in developing low molecular weight anti-PD-1/PD-1 agents, such as peptides, because of their improved tumor penetration. We recently developed a small anti-PD-L1 peptide and demonstrated its promising anti-tumor activity. In this study, we investigate multivalency as a strategy to increase the binding avidity and blocking efficiency of the anti-PD-L1 peptide.</p><p><strong>Methods: </strong>Multivalent peptide inhibitors are designed with multiple copies of a peptide inhibitor in a single molecule. We synthesized peptides with different valences and examined their activity. We also investigated how spacer length affects the activity of these multivalent peptides.</p><p><strong>Results: </strong>Using this strategy, we developed a multivalent peptide that demonstrated approximately 40 times higher blocking efficiency and improved stability compared to the original peptide. Increasing the valency enhanced the peptide's specificity, which is essential for minimizing side effects.</p><p><strong>Conclusions: </strong>Multivalency approach represents a promising platform for improving the efficacy of peptide-based checkpoint inhibitors.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2275-2288"},"PeriodicalIF":3.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation. 利用贝叶斯估计法确定哪些患者需要采集两点血样的峰值和谷值,而不是采集一点血样的谷值来评估万古霉素的 AUC。
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-11-01 Epub Date: 2024-10-21 DOI: 10.1007/s11095-024-03781-4
Ayako Suzuki, Masaru Samura, Tomoyuki Ishigo, Satoshi Fujii, Yuta Ibe, Hiroaki Yoshida, Hiroaki Tanaka, Fumiya Ebihara, Takumi Maruyama, Yukihiro Hamada, Hisato Fujihara, Fumihiro Yamaguchi, Fumio Nagumo, Toshiaki Komatsu, Atsushi Tomizawa, Akitoshi Takuma, Hiroaki Chiba, Yoshifumi Nishi, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto

Objectives: It is recommended to adjust the dose of vancomycin (VCM) with a target area under the concentration-time curve (AUC) of 400-600 μg·h/mL. Factors that affect the deviation between AUCs are estimated from the trough value alone and the trough and peak values using practical AUC-guided therapeutic drug monitoring (PAT) for vancomycin. In this study, factors that affect AUC were evaluated.

Methods: AUCs were estimated from a single trough value and trough and peak values, and the patients were classified into those who showed a 10% or greater deviation (deviation group) and those in whom the deviation was less than 10% (no-deviation group). Risk factors related to ≥ 10% deviation of AUC were identified by univariate and multivariate analysis.

Results: As a result of univariate and multivariate analysis of 30 patients in the deviation group and 344 patients in the no-deviation group, a creatinine clearance (CLcr) of ≥ 110 mL/min (odds ratio (OR) = 3.697, 95% confidence interval (CI) = 1.616-8.457, p = 0.002), heart failure with a brain natriuretic peptide (BNP) of ≥ 300 pg/mL (OR = 4.854, 95%CI = 1.199-19.656, p = 0.027), and the concomitant use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker (ACE-I/ARB) (OR = 2.544, 95%CI = 1.074-6.024, p = 0.034) were identified as risk factors of ≥ 10% deviation of AUC.

Conclusions: Estimation of AUC by two-point blood sampling for the trough and peak values rather than one-point blood sampling for the trough value is suggested to improve the prediction accuracy in patients with enhanced renal function, severe heart failure, and patients using ACE-I/ARB.

目标:建议调整万古霉素(VCM)的剂量,目标浓度-时间曲线下面积(AUC)为 400-600 μg-h/mL。使用实用的万古霉素 AUC 指导治疗药物监测 (PAT),仅从谷值以及谷值和峰值估算影响 AUC 之间偏差的因素。本研究对影响 AUC 的因素进行了评估:根据单一波谷值、波谷值和波峰值估算AUC,并将患者分为偏差大于或等于10%的患者(偏差组)和偏差小于10%的患者(无偏差组)。通过单变量和多变量分析确定了与AUC偏差≥10%相关的风险因素:对偏差组的 30 名患者和无偏差组的 344 名患者进行单变量和多变量分析的结果显示,肌酐清除率(CLcr)≥ 110 mL/min(几率比(OR)= 3.697,95% 置信区间(CI)= 1.616-8.457,P = 0.002)、脑钠肽(BNP)≥ 300 pg/mL 的心衰(OR = 4.854,95%CI = 1.199-19.656,p = 0.027),以及同时使用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂(ACE-I/ARB)(OR = 2.544,95%CI = 1.074-6.024,p = 0.034)被确定为 AUC 偏差≥10%的危险因素:结论:建议通过对谷值和峰值进行两点采血而不是对谷值进行一点采血来估计 AUC,以提高对肾功能增强患者、严重心衰患者和使用 ACE-I/ARB 患者的预测准确性。
{"title":"Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation.","authors":"Ayako Suzuki, Masaru Samura, Tomoyuki Ishigo, Satoshi Fujii, Yuta Ibe, Hiroaki Yoshida, Hiroaki Tanaka, Fumiya Ebihara, Takumi Maruyama, Yukihiro Hamada, Hisato Fujihara, Fumihiro Yamaguchi, Fumio Nagumo, Toshiaki Komatsu, Atsushi Tomizawa, Akitoshi Takuma, Hiroaki Chiba, Yoshifumi Nishi, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto","doi":"10.1007/s11095-024-03781-4","DOIUrl":"10.1007/s11095-024-03781-4","url":null,"abstract":"<p><strong>Objectives: </strong>It is recommended to adjust the dose of vancomycin (VCM) with a target area under the concentration-time curve (AUC) of 400-600 μg·h/mL. Factors that affect the deviation between AUCs are estimated from the trough value alone and the trough and peak values using practical AUC-guided therapeutic drug monitoring (PAT) for vancomycin. In this study, factors that affect AUC were evaluated.</p><p><strong>Methods: </strong>AUCs were estimated from a single trough value and trough and peak values, and the patients were classified into those who showed a 10% or greater deviation (deviation group) and those in whom the deviation was less than 10% (no-deviation group). Risk factors related to ≥ 10% deviation of AUC were identified by univariate and multivariate analysis.</p><p><strong>Results: </strong>As a result of univariate and multivariate analysis of 30 patients in the deviation group and 344 patients in the no-deviation group, a creatinine clearance (CLcr) of ≥ 110 mL/min (odds ratio (OR) = 3.697, 95% confidence interval (CI) = 1.616-8.457, p = 0.002), heart failure with a brain natriuretic peptide (BNP) of ≥ 300 pg/mL (OR = 4.854, 95%CI = 1.199-19.656, p = 0.027), and the concomitant use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker (ACE-I/ARB) (OR = 2.544, 95%CI = 1.074-6.024, p = 0.034) were identified as risk factors of ≥ 10% deviation of AUC.</p><p><strong>Conclusions: </strong>Estimation of AUC by two-point blood sampling for the trough and peak values rather than one-point blood sampling for the trough value is suggested to improve the prediction accuracy in patients with enhanced renal function, severe heart failure, and patients using ACE-I/ARB.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2161-2171"},"PeriodicalIF":3.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Mathematical Function Control-Based 3D Printed Tablets and Effect on Drug Release. 基于数学函数控制的 3D 打印片剂的开发及其对药物释放的影响
IF 3.5 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY Pub Date : 2024-11-01 Epub Date: 2024-10-21 DOI: 10.1007/s11095-024-03780-5
Honghe Wang, Indrajeet Karnik, Prateek Uttreja, Peilun Zhang, Sateesh Kumar Vemula, Michael A Repka

Purpose: The application of 3D printing technology in drug delivery is often limited by the challenges of achieving precise control over drug release profiles. The goal of this study was to apply surface equations to construct 3D printed tablet models, adjust the functional parameters to obtain multiple tablet models and to correlate the model parameters with the in vitro drug release behavior.

Methods: This study reports the development of 3D-printed tablets using surface geometries controlled by mathematical functions to modulate drug release. Utilizing fused deposition modeling (FDM) coupled with hot-melt extrusion (HME) technology, personalized drug delivery systems were produced using thermoplastic polymers. Different tablet shapes (T1-T5) were produced by varying the depth of the parabolic surface (b = 4, 2, 0, -2, -4 mm) to assess the impact of surface curvature on drug dissolution.

Results: The T5 formulation, with the greatest surface curvature, demonstrated the fastest drug release, achieving complete release within 4 h. In contrast, T1 and T2 tablets exhibited a slower release over approximately 6 h. The correlation between surface area and drug release rate was confirmed, supporting the predictions of the Noyes-Whitney equation. Differential Scanning Calorimetry (DSC) and Scanning Electron Microscope (SEM) analyses verified the uniform dispersion of acetaminophen and the consistency of the internal structures, respectively.

Conclusions: The precise control of tablet surface geometry effectively tailored drug release profiles, enhancing patient compliance and treatment efficacy. This novel approach offers significant advancements in personalized medicine by providing a highly reproducible and adaptable platform for optimizing drug delivery.

目的:3D 打印技术在给药领域的应用往往受到精确控制药物释放曲线的限制。本研究的目标是应用表面方程构建三维打印片剂模型,调整功能参数以获得多个片剂模型,并将模型参数与体外药物释放行为相关联:本研究报告了利用数学函数控制的表面几何形状来调节药物释放的三维打印片剂的开发过程。利用熔融沉积建模(FDM)和热熔挤出(HME)技术,使用热塑性聚合物生产出了个性化给药系统。通过改变抛物面的深度(b = 4、2、0、-2、-4 毫米)生产出不同形状的片剂(T1-T5),以评估表面曲率对药物溶出的影响:结果:表面曲率最大的 T5 制剂药物释放速度最快,在 4 小时内实现完全释放;相比之下,T1 和 T2 片剂释放速度较慢,约需 6 小时。差示扫描量热法(DSC)和扫描电子显微镜(SEM)分析分别验证了对乙酰氨基酚的均匀分散性和内部结构的一致性:片剂表面几何形状的精确控制有效地定制了药物释放曲线,提高了患者的依从性和治疗效果。这种新方法为优化给药提供了一个具有高度可重复性和适应性的平台,极大地推动了个性化医疗的发展。
{"title":"Development of Mathematical Function Control-Based 3D Printed Tablets and Effect on Drug Release.","authors":"Honghe Wang, Indrajeet Karnik, Prateek Uttreja, Peilun Zhang, Sateesh Kumar Vemula, Michael A Repka","doi":"10.1007/s11095-024-03780-5","DOIUrl":"10.1007/s11095-024-03780-5","url":null,"abstract":"<p><strong>Purpose: </strong>The application of 3D printing technology in drug delivery is often limited by the challenges of achieving precise control over drug release profiles. The goal of this study was to apply surface equations to construct 3D printed tablet models, adjust the functional parameters to obtain multiple tablet models and to correlate the model parameters with the in vitro drug release behavior.</p><p><strong>Methods: </strong>This study reports the development of 3D-printed tablets using surface geometries controlled by mathematical functions to modulate drug release. Utilizing fused deposition modeling (FDM) coupled with hot-melt extrusion (HME) technology, personalized drug delivery systems were produced using thermoplastic polymers. Different tablet shapes (T1-T5) were produced by varying the depth of the parabolic surface (b = 4, 2, 0, -2, -4 mm) to assess the impact of surface curvature on drug dissolution.</p><p><strong>Results: </strong>The T5 formulation, with the greatest surface curvature, demonstrated the fastest drug release, achieving complete release within 4 h. In contrast, T1 and T2 tablets exhibited a slower release over approximately 6 h. The correlation between surface area and drug release rate was confirmed, supporting the predictions of the Noyes-Whitney equation. Differential Scanning Calorimetry (DSC) and Scanning Electron Microscope (SEM) analyses verified the uniform dispersion of acetaminophen and the consistency of the internal structures, respectively.</p><p><strong>Conclusions: </strong>The precise control of tablet surface geometry effectively tailored drug release profiles, enhancing patient compliance and treatment efficacy. This novel approach offers significant advancements in personalized medicine by providing a highly reproducible and adaptable platform for optimizing drug delivery.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"2235-2246"},"PeriodicalIF":3.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142472344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmaceutical Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1